• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Video

Amid the Selling, Here's the Big Question Now

How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
By JAMES "REV SHARK" DEPORRE
Feb 25, 2021 | 04:43 PM EST
Stocks quotes in this article: GME

For the second time this week, higher interest rates and inflationary concerns triggered aggressive selling. The primary villain was a very poor 7-year bond auction, but much of the selling was caused by technical breakdowns in groups that traders have favored, like cannabis, special purpose acquisition companies, bitcoin-related names, gambling, and solar energy.

The short squeeze trade in GameStop (GME) and a few other names soaked up some liquidity and was a distraction, but the market pretty much took it in stride, unlike all the drama of three weeks ago.

The big difference between the selling Thursday and that which hit on Tuesday was that it was steady all day. There was a brief afternoon bounce attempt, and some buying that took us off the lows at the close but breadth was horrendous with just 840 gainers to over 6,900 decliners. It doesn't get much worse than that.

This highly correlated selling is how real corrections take place. There was no rotation, however, to soften the blows and the "reopen the economy" plays and financials all reversed after a positive open.

The big question now is how quickly do we find support? This correction is taking place at a time when economic optimism is building. The higher rates are mainly a function of more stimulus and stronger anticipated growth. Stocks may be expensive in places, but these are not the conditions that typically lead to a prolonged bear market. Presently this is just some routine corrective action, although losses never feel very routine. The uptrend is under pressure, but this is not a full-blown correction yet.

I'm not going to try to guess how much deeper this correction may go, but I'm already seeing many promising names that are looking washed out. Some of the SPACs, in particular, have limited risk as they approach their redemption levels.

Work on those shopping lists and enjoy the evening. I'll see you tomorrow.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, DePorre had no position in any security mentioned.

TAGS: Bonds | Investing basics | Stocks | Video

More from Video

One Tweet Pulls the Rug Out From Under the Indexes

James "Rev Shark" DePorre
Oct 6, 2020 4:44 PM EDT

Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.

A Technical Look at the New Dow Jones Industrial Average

Bruce Kamich
Aug 25, 2020 1:11 PM EDT

Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.

Conagra Brands Looks Tastier After Its Upgrade to Buy

Bruce Kamich
Dec 30, 2019 12:39 PM EST

CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.

Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts

Bruce Kamich
Oct 30, 2019 1:13 PM EDT

Breaking down an approach to the long side of this biotech stock.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:00 PM EDT CHRIS VERSACE

    AAP Podcast: This Solar Company Is a Head-Turner

    Listen to my interview with Brian Roth, CEO of sol...
  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login